The U.S. Food and Drug Administration authorized the maker of ZYN nicotine pouches to market the product as safer than cigarettes [1].
This decision marks a significant shift in how nicotine products are advertised in the U.S. By allowing a reduced-risk claim, the agency provides a regulatory pathway for companies to steer consumers away from combustible tobacco.
Philip Morris International, the owner of Swedish Match and the manufacturer of ZYN, is based in Stamford, Connecticut [1, 2]. The FDA said that specific versions of the product meet the criteria for a Modified Risk Tobacco Product (MRTP) [1, 5]. This designation allows the company to communicate to the public that the product is less harmful than traditional cigarettes [1, 3].
The authorization is not universal across the entire ZYN product line. The FDA limited the reduced-risk marketing claims to only three flavors: cool mint, citrus, and coffee [5].
According to industry reports, these are the first MRTP orders ever granted for nicotine pouches [2]. The process requires a company to demonstrate that the product will reduce exposure to harmful substances, or reduce the risk of tobacco-related disease [1, 5].
The agency's decision follows a review of the company's data regarding the risk profile of the pouches compared to smoking [1, 5]. While the FDA has authorized these specific claims for the identified flavors, the agency continues to regulate the broader marketing of nicotine products to prevent youth access [1].
“The FDA authorized the maker of ZYN nicotine pouches to market the product as safer than cigarettes.”
This ruling establishes a regulatory precedent for the nicotine pouch category, potentially encouraging other manufacturers to seek similar risk-reduction designations. By validating the 'safer' claim for specific flavors, the FDA is acknowledging a hierarchy of harm in tobacco products, which may accelerate the transition of adult smokers to non-combustible alternatives while tightening the focus on flavor-specific approvals.
